Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Dolutegravir.

ABSTRACT:

Background

Birth outcome data with dolutegravir exposure during pregnancy, particularly in the first trimester, are needed.

Setting

Data were prospectively collected from the Antiretroviral Pregnancy Registry and European Pregnancy and Paediatric HIV Cohort Collaboration.

Methods

We reviewed 2 large, independent antiretroviral pregnancy registries to assess birth outcomes associated with maternal dolutegravir treatment during pregnancy.

Results

Of 265 pregnancies reported to the Antiretroviral Pregnancy Registry, initial exposure to dolutegravir occurred at conception or first trimester in 173 pregnancies and during the second or third trimester in 92 pregnancies. There were 246 (92.8%) live births resulting in 255 neonates (9 twins), 6 (2.3%) induced abortions

SUBMITTER: Vannappagari V 

PROVIDER: S-EPMC6905407 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature